Quantcast

Latest Lamotrigine Stories

2010-08-25 08:00:00

WALTHAM, Mass., Aug. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar...

2010-08-12 10:46:00

SILVER SPRING, Md., Aug. 12 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned that the drug Lamictal (lamotrigine), approved to treat seizures and bipolar disorder, can cause aseptic meningitis, an inflammation of the protective membranes (meninges) that cover the brain and spinal cord not caused by bacterial infection. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The agency is working...

2010-07-27 13:00:22

While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology. Newer drugs with a higher risk of causing depression than other epilepsy drugs, such as levetiracetam, topiramate and vigabatrin, were found to increase the risk of...

2010-06-29 06:30:00

ATLANTA, June 29 /PRNewswire/ -- New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs)...

2010-04-20 09:17:39

Researchers have found that polytherapy with multiple anti-epileptic drugs (AEDs) did not result in greater adverse effects than monotherapy for patients with refractory epilepsy. This observational study also found AED load was not a factor in causing adverse effects, but suggests that individual susceptibility, type of AEDs used, and physicians' skills determine which patients suffer adverse effects. Results of this study are available today in Epilepsia, a journal published by...

2010-03-14 10:56:06

OHSU Doernbecher Children's Hospital is part of largest-ever NIH-funded pediatric epilepsy clinical trial to examine which of 3 standard treatments is most effective One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine. OHSU Doernbecher Children's Hospital is one of 32 comprehensive pediatric epilepsy centers nationwide selected...

2010-03-11 08:05:00

ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration (FDA) in 2008 for use as an add-on therapy for the treatment of partial-onset...

2010-03-04 08:30:10

CINCINNATI "“ The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy "“ the most common form of epilepsy in kids "“ has established an evidence-based approach for initial drug therapy. Published March 4 in the New England Journal of Medicine, data from the double-blind, randomized, comparative clinical trial fill a large information gap in the treatment of childhood absence epilepsy, also known...

2010-01-29 16:31:00

RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal®XR(TM) (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures. This is an expanded label, as Lamictal XR is approved for partial onset seizures (with or without secondary generalization) for...

2009-06-01 07:00:00

RESEARCH TRIANGLE PARK, N.C., June 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal(R)XR(TM) (lamotrigine) Extended-Release Tablets as once-a-day add-on therapy for epilepsy patients 13 years of age or older with partial onset seizures. Lamictal XR reduced seizures in patients who were inadequately controlled on current therapy. Lamictal XR reduced the frequency of partial seizures during a 19-week...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.